388 related articles for article (PubMed ID: 34638620)
1. Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy.
Hartman GD; Lambert-Cheatham NA; Kelley MR; Corson TW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638620
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization.
Li Y; Liu X; Zhou T; Kelley MR; Edwards P; Gao H; Qiao X
Redox Biol; 2014; 2():485-94. PubMed ID: 24624338
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo.
Jiang A; Gao H; Kelley MR; Qiao X
Vision Res; 2011 Jan; 51(1):93-100. PubMed ID: 20937296
[TBL] [Abstract][Full Text] [Related]
4. Suppression of choroidal neovascularization through inhibition of APE1/Ref-1 redox activity.
Li Y; Liu X; Zhou T; Kelley MR; Edwards PA; Gao H; Qiao X
Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4461-9. PubMed ID: 24970265
[TBL] [Abstract][Full Text] [Related]
5. APE1/Ref-1 as a Novel Target for Retinal Diseases.
Heisel C; Yousif J; Mijiti M; Charizanis K; Brigell M; Corson TW; Kelley MR
J Cell Signal; 2021; 2(2):133-138. PubMed ID: 34322687
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
Laev SS; Salakhutdinov NF; Lavrik OI
Bioorg Med Chem; 2017 May; 25(9):2531-2544. PubMed ID: 28161249
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
9. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.
Muniyandi A; Hartman GD; Song Y; Mijit M; Kelley MR; Corson TW
J Pharmacol Exp Ther; 2023 Jul; 386(1):15-25. PubMed ID: 37142441
[TBL] [Abstract][Full Text] [Related]
10. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease.
Campbell M; Doyle SL
Biochem Pharmacol; 2019 Jun; 164():321-325. PubMed ID: 31039332
[TBL] [Abstract][Full Text] [Related]
11. APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease.
Sahakian L; Robinson AM; Sahakian L; Stavely R; Kelley MR; Nurgali K
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002251
[TBL] [Abstract][Full Text] [Related]
12. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.
Kelley MR; Georgiadis MM; Fishel ML
Curr Mol Pharmacol; 2012 Jan; 5(1):36-53. PubMed ID: 22122463
[TBL] [Abstract][Full Text] [Related]
13. Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.
Sardar Pasha SPB; Sishtla K; Sulaiman RS; Park B; Shetty T; Shah F; Fishel ML; Wikel JH; Kelley MR; Corson TW
J Pharmacol Exp Ther; 2018 Oct; 367(1):108-118. PubMed ID: 30076264
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
15. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
16. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
Fu Z; Gong Y; Liegl R; Wang Z; Liu CH; Meng SS; Burnim SB; Saba NJ; Fredrick TW; Morss PC; Hellstrom A; Talukdar S; Smith LE
Cell Rep; 2017 Feb; 18(7):1606-1613. PubMed ID: 28199833
[TBL] [Abstract][Full Text] [Related]
17. The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease.
Caston RA; Gampala S; Armstrong L; Messmann RA; Fishel ML; Kelley MR
Drug Discov Today; 2021 Jan; 26(1):218-228. PubMed ID: 33148489
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Pathways Regulated by APE1/Ref-1 in Human Retinal Endothelial Cells.
Mijit M; Liu S; Sishtla K; Hartman GD; Wan J; Corson TW; Kelley MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674619
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis.
Sahakian L; Filippone RT; Stavely R; Robinson AM; Yan XS; Abalo R; Eri R; Bornstein JC; Kelley MR; Nurgali K
Inflamm Bowel Dis; 2021 Feb; 27(3):388-406. PubMed ID: 32618996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
